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Publications and Presentations of the Tuberculosis Trials Consortium 
(as of 1 February 2014)
I. Publications
1999 
Vernon A, Burman W, Benator D, Khan A, Bozeman L for the Tuberculosis Trials Consortium. Acquired rifamycin
mono-resistance among patients with HIV-related tuberculosis treated with supervised once weekly rifapentine and
isoniazid. Lancet 1999; 353:1843-47.
2001 
TB Trials Consortium. The Tuberculosis Trials Consortium: A Model for Clinical Trials Collaborations. Public 
Health Reports 2001; 116 (Supplement 1):41-49.
2002 
Centers for Disease Control & Prevention. Notice to Readers: Acquired Rifamycin Resistance in Persons with
Advanced HIV Disease Being Treated for Active Tuberculosis with Intermittent Rifamycin-Based Regimens. Morb
Mort Wkly Rep 2002; 51:214-5.
N Bock, T Sterling, CD Hamilton, C Pachucki, YC Wang, DS Conwell, A Mosher, M Samuels, and A Vernon and
the TBTC. A prospective, randomized, double-blind study of the tolerability of rifapentine 600 mg, 900 mg and
1200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Amer J Respir Crit Care Med 2002; 
165: 1526-1530.
TB Trials Consortium. Once-weekly rifapentine and isoniazid versus twice-weekly rifampin and isoniazid in the 
continuation phase of therapy for drug-susceptible pulmonary tuberculosis: a prospective, randomized clinical trial.
Lancet 2002; 360:528-34.
2003 
Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodges T, TBTC.
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
Am J Respir Crit Care Med 2003; 167:1341-7.
Burman W, Breese P, Weis S, Bock N, Bernardo J, Vernon A, TBTC. The effects of local review on informed
consent documents from a multicenter clinical trials consortium. Clinical Trials 2003;24:245-55.
2004 
Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K,
Goldberg S, Tuberculosis Trials Consortium. Pharmacokinetics of rifapentine 600, 900 and 1,200 mg during once-
weekly tuberculosis therapy. Am J Respir Crit Care Med 2004;169:1191-7.
Jasmer R, Bozeman L, Cave D, Saukkonen J, Schwartzman K, Metchock B, Burman W and the TB Trials
Consortium (TBTC). Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir
Crit Care Med 2004;170:1360-6.
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2005 
Bozeman L, Burman W, Metchock B, Welch L, Weiner M and the TB Trials Consortium (TBTC). Fluoroquinolone 
susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis
2005;40:386-91.
Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva -Trigo C, Zhao Z, Hodge T and
the Tuberculosis Trials Consortium. The association between acquired rifamycin resistance and
the pharmacokinetics of rifabutin and isoniazid among patients with HIV-related tuberculosis. Clin Infect Dis
2005;40:1481-91.
Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, Khan A, Zhao Z, and the Tuberculosis Trials 
Consortium. Evaluation of the Drug Interaction between Rifabutin and Efavirenz in Patients with HIV Infection and
Tuberculosis. Clin Infect Dis 2005; 41:1343–9
2006 
Sterling TR, Zhao Z, Khan A, Chaisson RE, Schluger N, Mangura B, Weiner M, Vernon A for the Tuberculosis
Trials Consortium. Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int
J Tuberc Lung Dis 2006;10(5):542–549.
Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis SE, King B, Mangura B, Weiner M, 
El-Sadr W, and the Tuberculosis Trials Consortium. Acquired Rifamycin Resistance with Twice-Weekly Treatment 
of HIV-related Tuberculosis. Am J Respir Crit Care Med 2006;173: 350-356.
Burman W, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao
Z, Vernon A, Chaisson RE, and the Tuberculosis Trials Consortium. Moxifloxacin versus Ethambutol in the First 2
Months of Treatment for Pulmonary Tuberculosis. Am J Respir Crit Care Med 2006; 174:331–338.
Khan A, Sterling TR, Reves R, Vernon A, Horsburgh CR, and the Tuberculosis
Trials Consortium. Lack of Weight Gain and Relapse Risk in a Large Tuberculosis Treatment Trial. Am J Respir
Crit Care Med 2006;174:344–348.
Sandman L, Mosher A, Khan A, Tapy A, Condos R, Ferrell S, Vernon A, and the Tuberculosis Trials Consortium.
Development and Implementation of a Quality Assurance Program in a Large Clinical Trials Consortium: 
Experience of the Tuberculosis Trials Consortium. Contemp Clin Trials 2006;27:554-60.
2007 
Conwell DS, Mosher A, Khan A, Tapy J, Sandman L, Vernon A, Horsburgh CR and the TB Trials Consortium
(TBTC). Factors Associated with Loss to Follow-up in a Large Tuberculosis Treatment Trial (TBTC Study 22).  
Contemp Clin Trials 2007;28:288-94.
Benator DA, Weiner M, Burman WJ, Vernon AA, Zhao ZA, Khan AE, Jones BE, Sandman L, Engle M, Silva-Trigo
C, Hsyu PH, Becker MI, and Peloquin CA, for the Tuberculosis Trials Consortium. Clinical evaluation of the
nelfinavir – rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Pharmacotherapy 2007 Jun;27(6):793-800.
Peloquin CA, Durbin D, Childs J, Sterling TR, Weiner M. Stability of anti-tuberculosis drugs mixed in food. Clin
Infect Dis 2007 Aug 15;45(4):521.
Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S, Agarwal V, Vernon A and the Tuberculosis
Trials Consortium. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of
moxifloxacin. Antimicrob Agents Chemother 2007 Aug;51(8):2861-6. Epub 2007 May 21.
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Burman W, Weis S, Vernon A, Khan A, Benator D, Jones B, Silva C, King B, Lahart C, Mangura B, Weiner M, el -
Sadr W. Frequency, severity and duration of immune reconstitution events in HIV -related tuberculosis. Int J Tuberc 
Lung Dis 2007;11:1282-9.
Breese PE, Burman WJ, Goldberg S, Weis S.Education Level, Primary Language, and Comprehension of the 
Informed Consent Process. Journal of Empirical Research on Human Research Ethics 2007: 69-79.
2008 
Hamilton CD, Stout JE, Goodman PC, Mosher A, Menzies R, Schluger NW, Khan A, Johnson JL, Vernon AN and
the Tuberculosis Trials Consortium. The Value of End-of-Treatment Chest Radiograph in Predicting Pulmonary
Tuberculosis Relapse. Int J Tuberc Lung Dis 2008 Sep;12(9):1059-64.
2009 
Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S,
Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A,
Chaisson RE; Tuberculosis Trials Consortium. Substitution of moxifloxacin for isoniazid during intensive phase 
treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. Epub 2009 Apr 30.
Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, Vernon A; Tuberculosis Trials Consortium.
Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis. Emerg Infect Dis. 
2009 Jul;15(7):1061-7.
2010 
Stout JE, Kosinski AS, Hamilton CD, Goodman PC, Mosher A, Menzies D, Schluger N, Khan A, Johnson JL; the 
Tuberculosis Trials Consortium. Effect of Improving the Quality of Radiographic Interpretation on the Ability to
Predict Pulmonary Tuberculosis Relapse(1). Acad Radiol. 2010 Feb;17(2):157-62. Epub 2009 Nov 11.
Kim EY, Nahid P, Hopewell PC, Kato-Maeda M. Novel hot spot of IS6110 insertion in Mycobacterium
tuberculosis. J Clin Microbiol. 2010 Apr;48(4):1422-4. Epub 2010 Feb 10.
Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato -
Maeda M; Tuberculosis Trials Consortium. Influence of M. tuberculosis lineage variability within a clinical trial for
pulmonary tuberculosis. PLoS ONE. 2010 May 20;5(5):e10753.
Yamshchikov AV, Kurbatova EV, Kumari M, Blumberg HM, Ziegler TR, Ray SM, Tangpricha V. Vitamin D status
and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis.
Am J Clin Nutr. 2010 Jul 7. [Epub ahead of print]
Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, Mac Kenzie WR, Bliven-Sizemore E, Johnson
JL, Vernon A. The effects of tuberculosis, race and human gene SLCO1B1 polymorphisms on rifampin
concentrations. Antimicrob Agents Chemother. 2010 Jul 26. [Epub ahead of print]
Weiner M, Prihoda TJ, Burman W, Johnson JL, Goldberg S, Padayatchi N, Duran P, Engle M, Muzanye G,
Mugerwa RD, Sturm AW. Evaluation of time to detection in broth culture as an endpoint for tuberculosis trials. J
Clin Microbiol. In press.
2011 
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Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, Dunbar D, Jost, Jr KC, Diem L, Metchock B,
Eisenach K, Dorman S, Goldberg S. Geographic Differences in Time to Culture Conversion in Liquid Media: 
Tuberculosis Trials Consortium Study 28.Culture Conversion Is Delayed in Africa. PLoS ONE 2011;6:e18358.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies
D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials
Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection.
N Engl J Med. 2011 Dec 8;365(23):2155-66.
Heilig CM, Chia D, El-Sadr WM, Hirsch-Moverman Y, Mac Kenzie WR, Saukkonen J, Villarino ME, Padayatchi 
N. Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis. IRB:Ethics & Human
Research. 2011;33:10-17.
Nahid P, Saukkonen J, Mac Kenzie W, Johnson JL, Phillips PJ, Andersen J, Bliven E, Belisle J, Boom H,
Luetkemeyer A, Campbell T, Eisenach K, Hafner R, Lennox J, Makhene M, Swindells S, Villarino E, Weiner M,
Benson C, Burman W. Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap. Am J Respir Crit Care 
Med. 2011 Jul 14.
2012 
Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard C, Fuchs EJ, Melia MT, Burman
WJ, Dorman SE. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in
health volunteers. Clinical Pharmacology & Therapeutics. 2012;91:881-8.
Bliven-Sizemore EE, Johnson JL, Goldberg S, Burman WJ, Villarino ME, Chaisson RE, Consortium FT. Effect of
HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment. Int J Tuberc Lung Dis. 
2012;16:473-9.
Goodridge A, Cueva C, Lahiff M, Muzanye G, Johnson JL, Nahid P, Riley LW. Anti -phospholipid antibody levels
as biomarker for monitoring tuberculosis treatment response. Tuberculosis. 2012;92:243 -7.
Dorman SE, Goldberg S, Stout JE, Muzanye G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R,
Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW, the Tuberculosis Trials
Consortium. Substitution of Rifapentine for Rifampin during intensive phase treatment of pulmonary tuberculosis: 
Study 29 of the Tuberculosis Trials Consortium. J Infect Dis. 2012;206:1030-1040.
Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, Mac Kenzie WR, Weiner M, McIlleron
H, Kirkpatrick CM. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients
with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2012;56:3857-63.
Padayatchi N, Mac Kenzie WR, Hirsch-Moverman Y, Feng PJ, Villarino ME, Saukkonen J, Heilig CM, Weiner M,
El-Sadr WM. Lessons from a randomised clinical trial for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis
2012;16:1582-7. 
Lamunu D, Chapman KN, Nsubuga P, Muzanyi G, Mulumba Y, Mugerwa MA, Goldberg S, Bozeman L, Engle M,
Saukkonen J, Mastranunzio S, Mayanja-Kizza H, Johnson JL. Reasons for non-participation in an international 
multicenter trial of a new drug for tuberculosis treatment. Int J Tuberc Lung Dis 2012;16:480 -5.
2013 
Hales CM, Heilig CM, Chaisson R, Leung CC, Chang KC, Goldberg SV, Gordin F, Johnson JL, Muzanyi G,
Saukkonen J, Vernon A, Villarino ME, Burman WJ. The association between symptoms and microbiologically
defined response to tuberculosis treatment. Ann Am Thorac Soc 2013;10:18-25.
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De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA.





Nyendak MR, Park B, Null MD, Baseke J, Swarbrick G, Mayanja-Kizza H, Nsereko M, Johnson DF, Gitta P,
 
Okwera A, Goldberg S, Bozeman L, Johnson JL, Boom WH, Lewinsohn DA, Lewinsohn DM; Tuberculosis
 
Research Unit and the Tuberculosis Trials Consortium.
 
Mycobacterium tuberculosis Specific CD8(+) T Cells Rapidly Decline with Antituberculosis Treatment.
 
PLoS One. 2013 Dec 4;8(12):e81564.

De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA.

Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.
 
PLoS One. 2013 Apr 18;8(4):e61002.

Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM,
 
Sterling TR, Villarino ME, Mac Kenzie WR. Cost-effectiveness of a 12-dose regimen for treating latent 

tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013 Dec;17(12):1531-7.

Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JA, Mac Kenzie W, Peloquin CA. Pharmacokinetic 





Hales CM, Heilig CM, Chaisson R, Leung CC, Chang KC, Goldberg SV, Gordin F, Johnson JL, Muzanyi G,
 
Saukkonen J, Vernon A, Villarino ME, Burman WJ. The association between symptoms and microbiologically
 
defined response to tuberculosis treatment. Ann Am Thorac Soc. 2013 Feb;10(1):18-25.

Kolwijck E, Friedrich SO, Karinja MN, van Ingen J, Warren RM, Diacon AH. Early stationary phase culture
 
supernatant accelerates growth of sputum cultures collected after initiation of anti-tuberculosis treatment.
 
Clin Microbiol Infect. 2013 Nov 4. doi: 10.1111/1469-0691.12441. [Epub ahead of print]
 
2014 
Reves R, Heilig CM, Tapy J, Bozeman L, Kyle RP, Hamilton CD, Bock N, Narita M, Wing D, Hershfield E,
 
Goldberg S, and the Tuberculosis Trials Consortium. Intermittent treatment for tuberculosis in patients not receiving
 
isoniazid because of intolerance or drug resistance. IJTLD, in press
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II. Presentations and Abstracts
1997 
Bozeman L, Vernon A, Crawford J, Glickman S, Dansbury K, Villarino E and the USPHS Rifapentine Trials Group.
Drug susceptibility testing (DST) of M. tuberculosis (M.TB) isolates from patients enrolled in a clinical trial..
[abstract]. Am J Respir Crit Care Med 1997;155:A220.
Rifapentine Trial Group: Design of USPHS Study 22: A trial of once weekly isoniazid and rifapentine in the 
continuation phase of TB treatment.[abstract] Am J Respir Crit Care Med 1997;155:A255.
Vernon A, Villarino E, O’Brien R et al. Relapse with rifampin mono-resistant TB (RMR-TB) in HIV-positive TB
patients treated with a once weekly rifapentine-containing regimen [abstract]. Int J Tuberc Lung Dis 1997;1
Suppl.A:S51-2.
1998 
Benator D, Burman W, Chaisson R, and USPHS Study 22 Investigators. Acquired rifamycin monoresistant 
tuberculosis among HIV-infected patients treated with once-weekly isoniazid and rifapentine. 5
th 
Conference on
Retroviruses and Opportunistic Infections. Chicago, IL, February 1998.
Vernon A, Khan A, Bozeman L, et al. Update on US Public Health Service (USPHS) Study 22: A trial of once
weekly isoniazid (INH) & rifapentine (RFP) in the continuation phase of TB treatment [abstract]. Am J Respir Crit 
Care Med 1998;157:A467. 
Vernon A. TB Clinical Trials in the US. Oral presentation, evening symposium, American Thoracic Society
International Conference, Chicago, IL, April 1998.
1999 
Burman W, Vernon A, Benator D for the TB Trials Consortium. Isoniazid, rifampin and rifapentine in human
plasma: no need to add ascorbic acid to maintain stability. [abstract]. Am J Respir Crit Care Med 1999;159:A496.
Horsburgh CR, Reichman LB, Vernon A, Gordin F, Villarino ME, O'Brien R, for the TBTC Investigators.
Establishment of the Tuberculosis Trials Consortium (TBTC). Invited presentation, 1999 American Thoracic 
Society International Conference, San Diego, CA.
Peloquin CA, Vernon A, Burman W, Benator D, for the TB Trials Consortium. Pharmacokinetics of rifapentine,
rifampin, isoniazid in TB patients. [abstract]. Am J Respir Crit Care Med 1999;159:A416.
Bock N, for the Tuberculosis Trials Consortium. Safety and tolerability of once-weekly rifapentine/isoniazid (INH)
vs. twice-weekly rifampin/INH in the continuation phase therapy of pulmonary tuberculosis in HIV-negative adults
in USPHS Study 22. Poster presentation, 30
th 
IUATLD World Conference on Lung Health, Madrid (Spain),
September 1999. 
2000 
A Vernon for the TB Trials Consortium. TBTC Study 22 (Rifapentine Trial): Preliminary Results in HIV -negative 
Patients. Invited presentation at Rifapentine Evening Symposium, Meeting of the European Region of the IUATLD,
Budapest (Hungary), April 2000.
A Vernon for the TB Trials Consortium. TBTC Study 22 (Rifapentine Trial): Preliminary Results in HIV -negative 
Patients. [abstract]. Am J Respir Crit Care Med 2000; 161(suppl):A252.
A Catanzaro, R Horsburgh for the TB Trials Consortium. TBTC Study 22: Risk Factors for Relapse with Once -
weekly Isoniazid/rifapentine (HP) in HIV-negative TB Patients. [abstract]. Am J Respir Crit Care Med 2000; 
161(suppl):A252.
F.Gordin, R.Chaisson for the TB Trials Consortium. TBTC Study 22: Risk Factors for Relapse with Twice -weekly
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161(suppl):A252.
Z. Taylor, Qualls N, Vernon A, Villarino E, O’Brien R. A prevention effectiveness study of rifapentine in the 
continuation phase of therapy for active pulmonary tuberculosis.[abstract]. Am J Respir Crit Care Med 2000; 
161(suppl):A524.
A. Khan, L. Sandman, A. Mosher, D. Pizzano for the TB Trials Consortium. TBTC Study 22 (Rifapentine Trial): 
Preliminary quality assurance results in HIV-negative Patients. [abstract]. Am J Respir Crit Care Med 2000; 
161(suppl):A645.
Villarino ME, O’Brien RJ for the TB Trials Consortium. TBTC Study22: Rifapentine Clinical Trial. Results in
HIV-negative patients with pulmonary tuberculosis. Presented at the Australian Society of Microbiology
Conference on TB in the New Millenium, June 2000.
Catanzaro A, Villarino ME, for the TB Trials Consortium. Rate of and risk factors for relapse after once-weekly
treatment with isoniazid and rifapentine for pulmonary tuberculosis. Presented at the Australian Society of
Microbiology Conference on TB in the New Millenium, June 2000.
Reichman LB, Villarino ME, for the TB Trials Consortium. Evaluation of the standard short course therapy (SSCT)
for treatment of pulmonary tuberculosis (TB): results from TBTC Study 22. Presented at the Australian Society of
Microbiology Conference on TB in the New Millenium, June 2000.
Burman W, for the Tuberculosis Trials Consortium. Should tuberculosis treatment be extended in selected patients?
Data from TBTC Study 22 and review of previous studies (poster). 38
th 
Annual IDSA Meeting, New Orleans LA,
Sept 7-10, 2000
Chaisson RE, El-Sadr W, for the TB Trials Consortium. Weekly Rifapentine and INH versus Twice Weekly
Rifampin/INH in the Continuation Phase of Therapy for HIV Negative Patients with Pulmonary Tuberculosis (TB): 
Final Results; USPHS Study 22 (poster). ICAAC, 2000.
2001 
Carol Dukes Hamilton, William N. Rom, for the TB Trials Consortium. Clinical Correlates of Sub -optimal 
Response to Tuberculosis (TB) Therapy in Humans (abstract). Keystone Symposium, February 2001.
Weiner M, Khan A, Benator D, Peloquin C, Burman W, and the TB Trials Consortium. Low Isoniazid (INH)
Levels Are Associated with TB Treatment Failure/Relapse with Once-Weekly Rifapentine (RPT) and INH 
[abstract]. Am J Respir Crit Care Med 2001; 163(suppl):A498.
Peloquin C, Benator D, Hayden K, Pizzano D, and the TB Trials Consortium. Low Rifapentine, Rifampin, &
Isoniazid Plasma Levels Are Not Predicted by Clinical And Demographic Features [abstract]. Am J Respir Crit 
Care Med 2001; 163(suppl):A498.
A. Vernon, D. Benator, N. Shah, T. Hodge and the TB Trials Consortium. N-Acetyl transferase type 2 Genotype 
Correlates with Treatment Failure or Relapse of Intermittent Isoniazid-containing Short-course Therapy [abstract].
Am J Respir Crit Care Med 2001; 163(suppl):A498.
N. Bock, Sterling T, Pachucki C, Conwell D, Wang YC, for the TB Trials Consortium. Tolerability of Once -weekly
Rifapentine 900 mg plus INH vs Once-weekly Rifapentine 600 mg plus INH during Continuation Phase Treatment 
of Pan-susceptible Tuberculosis in HIV-negative Adults [abstract]. Am J Respir Crit Care Med 2001; 
163(suppl):A497. (poster).
Weiner M, Vernon A, Benator D, Khan A, Peloquin C, Hodge T and Burman W, for the TB Trials Consortium.
Low Isoniazid Levels Are Associated with Tuberculosis Treatment Failure or Relapse with Once-Weekly, Short 
Course Rifapentine and Isoniazid [abstract]. Int Journal TB and Lung Disease 2001;5 (Supp 1):S120. Poster
presented at 32
nd 
World Conference of the International Union Against Tuberculosis and Lung Disease, Paris
  
     
 
                
            
         
     
 
                
            
       
 
 
                
             
         
    
 
               
           
           
 
                
            
        
 
                   
         
         
    
 
                 
           
        
      
 
              
            
        
 
              
          
             
     
 
               
                
          
                
   
 
                 
        
           




Burman W, Breese P, Weis S, Bock N, Bernardo J, Vernon A, for the TB Trials Consortium. The effects of local 
review on informed consent documents from a multicenter clinical trials consortium. Poster presented at the 15 
th 
Annual Applied Research Ethics National Association (ARENA) Meeting, Boston MA, December 2001.
2002 
L Sandman,a Khan, A Mosher, J Tapy, A Vernon, and the TB Trials Consortium. Data Quality Assurance in the 
Tuberculosis Trials Consortium: A Partnership Approach. Sumbmitted to 2002 Society for Clinical Trials
conference, Arlington VA. Controlled Clinical Trials 2002; 23:63S (poster).
D Conwell, A Khan, J Tapy, L Sandman, A Mosher, S Barnes, M Bhattacharya, A Vernon, and the TB Trials
Consortium (TBTC). Preventable Loss to Follow-Up (F/U) in a Large TB Treatment Trial (TBTC Study 22).
Submitted to American Thoracic Society 2002 International Conference [abstract]. Am J Respir Crit Care Med
2002; 165 (suppl):A293. (poster).
A Khan, R Reves, T Sterling, A Vernon, S Weis, and the TB Trials Consortium (TBTC). Weight, Body Mass
Index, and Treatment Outcome in a Large TB Treatment Trial (TBTC Study 22). Submitted to American Thoracic 
Society 2002 International Conference [abstract]. Am J Respir Crit Care Med 2002; 165 (suppl):A293. (poster).
L Bozeman, R Chaisson, G Dickinson, B Mangura, N Schluger, T Sterling, A. Vernon, Y -C Wang, and the TB
Trials Consortium. Mortality in a Large TB Treatment Trial. Submitted to American Thoracic Society 2002
International Conference [abstract]. Am J Respir Crit Care Med 2002; 165 (suppl):A713 (poster).
L Bozeman, W Burman, F Gordin, B Metchock, C Peloquin, M. Weiner, and the TB Trials Consortium (TBTC).
Fluoroquinolone Susceptibility Among Mycobacterium tuberculosis Isolates from the United States and Canada.
Submitted to American Thoracic Society 2002 International Conference [abstract]. Am J Respir Crit Care Med
2002; 165 (suppl):A18 (oral presentation).
M Bhattacharya, L Bozeman, W Burman, D Cave, B Metchock, J Tapy, A Vernon, C Woodley, and the TB Trials
Consortium (TBTC). Usefulness of DNA fingerprinting of Mycobacterium tuberculosis in a large clinical trial of
tuberculosis treatment. Submitted to American Thoracic Society 2002 International Conference [abstract]. Am J 
Respir Crit Care Med 2002; 165 (suppl):A713 (poster).
CA Peloquin, N Bock, M Weiner, A Vernon and TB Trials Consortium (TBTC). Pharmaco -kinetics of Rifapentine 
Used at High Doses in Patients with TB Disease. Submitted to American Thoracic Society 2002 International 
Conference [abstract]. Am J Respir Crit Care Med 2002; 165 (suppl):A713 (poster).
A Vernon, CR Horsburgh, B Burman, and the TB Trials Consortium. TBTC Study 22/Once -Weekly
Isoniazid/Rifapentine (HP1) Vs Twice-Weekly Isoniazid/Rifampin (HR2) In HIV-Negative TB Patients. – In
Whom Can Once-Weekly Therapy Be Safely Used? [abstract 146]. Program and Abstracts of the 4 
th 
World
Congress on Tuberculosis, Bethesda MD, June 2002; 86.
Benator D, Burman W, Vernon A, Weiner M, Villarino E, Jones B, Silva C, Weis S, Lahart C, King B, Mangura B,
Weiner M, El-Sadr W and the TB Trials Consortium (TBTC). Acquired Rifamycin Resistance is Associated with
Intermittent Treatment of Tuberculosis in Patients with Advanced HIV infection: Preliminary Results o f TBTC
Study 23 and review of previous studies [abstract]. Program and Abstracts of the 4 
th 
World Congress on
Tuberculosis, Bethesda MD, June 2002; 12-13.
A Vernon, A Khan, B Burman, CR Horsburgh, and the TB Trials Consortium. TBTC Study 22: Risk Factors For
Failure/Relapse With Once-Weekly Isoniazid/Rifapentine (Hp) Or Twice-Weekly Isoniazid/Rifampin (Hr) In
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